Product Information for the Patient

Venlafaxine Retard Viatris75 mg Extended-Release Hard Capsules EFG

Venlafaxine Retard Viatris 150 mg Extended-Release Hard Capsules EFG

Read this entire product information carefully before starting to take this medication,because it contains important information for you.

• Keep this product information, as you may need to read it again.

If you have any questions, consult your doctor or pharmacist.

• This medication has been prescribed only for you and should not be given to others, even if they have the same symptoms as you, as it may harm them.
• If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this product information. See section 4.

6. Contents of the pack and additional information

Venlafaxina Retard Viatris contains the active ingredient venlafaxina and is an antidepressant that belongs to a group of medicines called serotonin and noradrenaline reuptake inhibitors (SNRIs). This group of medicines is used to treat depression and other conditions, such as anxiety disorders.

Venlafaxina is a treatment for adults with depression or to prevent the recurrence of major depressive episodes.Venlafaxinais also a treatment for adults with the following anxiety disorders: generalized anxiety disorder, social anxiety disorder (fear or avoidance of social situations), panic disorder (panic attacks). Treating depression and anxiety disorders properly is important to help you feel better. If not treated, your condition may not go away or may worsen and become harder to treat.

Do not take Venlafaxina Retard Viatris:

Warnings and precautions

Consult your doctor or pharmacist before starting to takeVenlafaxina Retard Viatris:

• If you are taking other medications that, taken with venlafaxine, may increase the risk of developing serotonin syndrome (see the section “Other medications and Venlafaxina Retard Viatris”).
• If you have eye problems, such as certain types of glaucoma (increased eye pressure) or if your ophthalmologist has told you that you may be at a higher risk of developing glaucoma.
• If you have a history of high blood pressure or if you have recently had a heart attack.
• If you, or someone in your family, have a history of heart problems.
• If you have been told that you have an abnormal heart rhythm.
• If you have a history of seizures (convulsions).
• If you have a history of low sodium levels in the blood (hyponatremia). Additionally, if you are an elderly person, you are taking diuretics (tablets that can cause increased urine production) or are dehydrated (for example, due to severe diarrhea or disease).
• If you have a tendency to develop bleeding or bruising easily (history of bleeding disorders), if you are taking other medications that thin the blood and may increase the risk of bleeding, or if you are pregnant (see “Pregnancy and breastfeeding”).
• If you have a history of mania or bipolar disorder (feeling overly excited or euphoric).
• If you have a history of aggressive behavior. You may feel aggressive, especially during the initial stages of treatment with venlafaxine, if your dose is changed or when you stop taking it.
• If you have diabetes (this medication may affect blood sugar levels).
• If you are taking any weight loss medication.

During treatment

• This medication may cause an increase in blood pressure or cholesterol levels. Your doctor should regularly check your blood pressure and cholesterol levels.
• If you experience restlessness or difficulty sitting or staying still, which may occur during the initial stages of treatment, talk to your doctor or pharmacist.
• If you are about to undergo a urine test to detect certain medications, this medication may affect the results. Inform your doctor or hospital staff that you are taking this medication.
• The capsules ofVenlafaxina Retard Viatriscontain beads, the insoluble part of which is eliminated and may be observed in the stool.

Do not drink alcohol during treatment with Venlafaxina Retard Viatris, as it may cause extreme fatigue and unconsciousness. Taking it with certain medications and/or alcohol may worsen the symptoms of depression and other conditions, such as anxiety disorders.

Thoughts of suicide and worsening of depression or anxiety disorder:

If you are depressed and/or have anxiety disorders, you may sometimes have thoughts of self-harm or suicide. These thoughts may increase when starting to take antidepressants, as all these medications require time to work, usually around two weeks, but sometimes longer. These thoughts may also occur when reducing the dose or during the suspension of treatment with venlafaxina.

It is more likely to happen:

-If you have had previous thoughts of suicide or self-harm.

-If you are a young adult. Information from clinical trials has shown a higher risk of suicidal behavior in young adults (under 25 years) with psychiatric disorders treated with an antidepressant.

If you have thoughts of suicide or self-harm at any time,contact your doctor or go to the hospital immediately.

It may be helpful to tell a close family member or friendthat you are depressed or have an anxiety disorder and ask them to read this leaflet. You can ask them to tell you if they think your depression or anxiety is getting worse or if they are concerned about changes in your behavior.

Dry mouth

10% of patients treated with venlafaxine report dry mouth. This may increase the risk of developing dental caries. Therefore, you should take good care of your dental hygiene.

Diabetes

Your blood glucose levels may be affected by venlafaxina, so you may need to adjust the dose of your diabetes medication.

Sexual dysfunction

Some medications in the group to whichVenlafaxina Retard Viatrisbelongs (called ISRS/IRSN) may cause symptoms of sexual dysfunction (see section4). In some cases, these symptoms persist after stopping treatment.

Children and adolescents

Normally, venlafaxina should not be used to treat children and adolescents under 18 years old. Additionally, you should know that in patients under 18 years old, there is a higher risk of adverse effects such as suicidal behavior, suicidal thoughts, and hostility (mainly aggression, confrontational behavior, and irritability) when taking this type of medication. However, your doctor may prescribe this medication to patients under 18 years old when they decide it is the best option for the patient. If your doctor has prescribed this medication to a patient under 18 years old and wants to discuss this decision, please see your doctor again. You should inform your doctor if any of the symptoms listed above worsen or if you experience complications when patients under 18 years old are taking venlafaxina. Studies conducted in this age group with this medication have not shown with certainty whether this medication affects growth, maturation, and cognitive and behavioral development.

Other medications and Venlafaxina Retard Viatris

Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription or natural remedies and herbal products.

Your doctor must decide if you can takevenlafaxinawith other medications.

• Do not take irreversible monoamine oxidase inhibitors (IMAO), used to treat depression or Parkinson's disease, with venlafaxina. Inform your doctor if you have taken any of these medications in the last 14 days. (IMAO: see section “What you need to know before starting to take Venlafaxina Retard Viatris”).

Serotonin syndrome: a potentially life-threatening disease or reactions similar to malignant neuroleptic syndrome (SNM) (see section “Possible side effects”), may occur with treatment with venlafaxina, particularly when taken with other medications.

Examples of these medications include:

• Triptans (used to treat migraines, for example, sumatriptan, zolmitriptan).
• Other medications to treat depression, for example, ISRN, ISRS, tricyclic antidepressants, or medications containing lithium.
• Medications containing amphetamines (used to treat attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity).
• Medications containing linezolid, an antibiotic (used to treat infections).
• Medications containing moclobemide, an IMAO (used to treat depression).
• Medications containing sibutramine (used to lose weight).
• Medications containing tramadol, fentanyl, tapentadol, pethidine, or pentazocine (used to treat severe pain).
• Medications containing dextromethorphan (used to treat cough).
• Medications containing methadone (used to treat opioid addiction or severe pain).
• Medications containing methylene blue (used to treat high levels of methemoglobin in the blood).
• Products containing St. John's Wort (also known as “Hypericum perforatum”, a natural remedy or herbal product used to treat mild depression).
• Products containing tryptophan (used to treat problems such as sleep and depression).
• Antipsychotics (used to treat a disease with symptoms such as hearing, seeing, or feeling things that are not present, false beliefs, unusual suspicions, irrational interpretations, and becoming withdrawn).

The signs and symptoms of serotonin syndrome may include a combination of the following: restlessness, hallucinations, loss of coordination, rapid heartbeat, increased body temperature, rapid changes in blood pressure, hyperactive reflexes, diarrhea, coma, nausea, vomiting.

In its most severe form, serotonin syndrome may resemble Malignant Neuroleptic Syndrome (SNM). The signs and symptoms of SNM may include a combination of fever, rapid heartbeat, sweating, intense muscle rigidity, confusion, mood changes, increased muscle enzymes (determined by blood test).

Inform your doctor immediately or go to the nearest hospital emergency department if you think you are experiencing serotonin syndrome or SNM.

You should inform your doctor if you are taking medications that may affect heart rhythm.

Examples of these medications include:

• Antiarrhythmics such as quinidine, amiodarone, sotalol, or dofetilide (used to treat abnormal heart rhythm).
• Antipsychotics such as thioridazine (see also “Serotonin syndrome” above).
• Antibiotics such as erythromycin or moxifloxacin (used to treat bacterial infections).
• Antihistamines (used to treat allergies).

The following medications may interact with venlafaxina and should be used with caution. It is especially important to mention to your doctor or pharmacist if you are taking medications that contain:

• Medications that inhibit certain enzymes (CYP3A4) such as:

• Atazanavir, indinavir, nelfinavir, ritonavir, saquinavir (medications used to treat HIV).
• Ketoconazole, itraconazole, voriconazole, posaconazole (antifungal medications).
• Clarithromycin and telithromycin (antibiotics).

• Haloperidolor risperidone (used to treat psychiatric diseases).
• Metoprolol (a beta-blocker used to treat high blood pressure and heart problems).

Taking Venlafaxina Retard Viatris with food, drinks, and alcohol

Venlafaxina Retard Viatris should be taken with food (see section3 “How to take Venlafaxina Retard Viatris”).

Do not drink alcohol during treatment with Venlafaxina Retard Viatris. Taking it with alcohol may cause extreme fatigue and unconsciousness, and worsen the symptoms of depression and other conditions, such as anxiety disorders.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before taking this medication. You should only take venlafaxina after discussing the possible benefits and risks for the fetus with your doctor.

Make sure your midwife and/or doctor know that you are taking venlafaxina. When taken during pregnancy, similar medications (ISRS) may increase the risk of a serious condition in newborns, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and turn blue. These symptoms usually start within the first 24 hours after the baby's birth. If this happens to your baby, contact your midwife and/or doctor immediately.

If you are taking this medication during pregnancy, in addition to breathing difficulties, another symptom your baby may have when born is problems with breastfeeding. If you observe that your baby has these symptoms when born and are concerned, contact your doctor and/or midwife, who can advise you.

If you take venlafaxina in the final stages of pregnancy, there may be a higher risk of excessive vaginal bleeding shortly after delivery, especially if you have a history of bleeding disorders. Your doctor or midwife should know that you are taking venlafaxina so they can advise you.

If you are breastfeeding, ask your doctor for advice. Venlafaxina passes into breast milk. There is a risk that it may affect the baby. Therefore, you should discuss the case with your doctor, and they will decide whether you should stop breastfeeding or stop taking venlafaxina.

Driving and using machines

Do not drive or operate machinery until you know how venlafaxina affects you, as this medication may affect your judgment, reasoning, or ability to drive or operate machinery.

This medication contains less than 1 mmol of sodium (23 mg) per capsule; it is essentially “sodium-free”.

Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

The usual recommended initial dose for the treatment of depression, generalized anxiety disorder, and social anxiety disorder is 75 mg per day. Your doctor may gradually increase the dose and, if necessary, even more, up to a maximum of 375 mg per day for depression. If you are being treated for panic disorder, your doctor will start with a lower dose (37.5 mg) and then gradually increase the dose. The maximum dose for generalized anxiety disorder, social anxiety disorder, and panic disorder is 225 mg/day. It is possible that your doctor will recommend that you take this medication for several months depending on your condition; it is also likely that he will make regular reviews during treatment.

Take venlafaxine approximately at the same time every day, either in the morning or at night. The capsules must be swallowed whole with liquids and should not be opened, crushed, chewed, or dissolved.

This medication should be taken with food.

If you have liver or kidney problems, talk to your doctor, as your dose of this medication may need to be adjusted.

Do not stop taking venlafaxine without consulting your doctor (see section "If you interrupt treatment with Venlafaxina Retard Viatris").

Use in children and adolescents

Usually, the use of venlafaxine is not recommended in children and adolescents (see section 2).

If you take more Venlafaxina Retard Viatris than you should

Call your doctor or pharmacist immediately if you take more of this medication than prescribed by your doctor.You can also contact the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount taken.

Overdose can put your life at risk, especially with the simultaneous taking of certain medications and/or alcohol (see Taking Venlafaxina Retard Viatris with other medications).

The symptoms of a possible overdose may include rapid or slow heartbeats or changes in heart electrical activity that can be observed through tests, decreased blood pressure, dizziness, changes in alertness (ranging from drowsiness to coma), blurred vision, seizures or convulsions, and vomiting.

If you forgot to take Venlafaxina Retard Viatris

If a dose has not been taken, take it as soon as you remember. However, if it is already time for your next dose, skip the missed dose and take only one dose as usual.Do not take a double dose to compensate for the missed doses. Do not take more than the daily dose of slow-release venlafaxine that has been prescribed for you.

If you interrupt treatment with Venlafaxina Retard Viatris

Do not stop taking your treatment or reduce the dose without consulting your doctor, even if you feel better. If your doctor thinks you no longer need venlafaxine, he may ask you to gradually reduce the dose before stopping treatment completely. It is known that adverse effects occur when people stop using this medication, especially when it is stopped suddenly or if the dose is reduced very quickly. Some patients may experience symptoms such as suicidal thoughts, aggression, fatigue, dizziness, drowsiness, headache, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, anxiety, nervousness, agitation, confusion, ringing in the ears, numbness, or, in rare cases, a feeling of electric shock, weakness, sweating, seizures, tremors, symptoms similar to the flu, vision problems, and increased blood pressure (which can cause headaches, dizziness, ringing in the ears, sweating, etc.).

Your doctor will advise you on how to gradually stop treatment with venlafaxine. This process may take several weeks or months. For some patients, treatment may be gradually stopped over several months or more. If you experience any of these or other symptoms that bother you, consult your doctor for further advice.

If you have any other doubts about the use of this medication, ask your doctor or pharmacist.

Like all medicines, this medicine can cause side effects, although not everyone will experience them.

If you experience any of the following side effects, do not take more venlafaxine. Inform your doctor immediately or go to the nearest hospital emergency department:

Rare (may affect up to 1 in 1,000 people):

• Swelling of the face, mouth, tongue, throat, hands, or feet, or itching, rash, hives, difficulty swallowing or breathing.

Uncommon (may affect up to 1 in 1,000 people)

• Chest tightness, wheezing, difficulty swallowing or breathing.
• Severe skin eruptions, itching, or hives (areas of pale or red skin that usually itch).

• Severe skin rash that leads to severe blisters and skin peeling.
• Signs and symptoms of serotonin syndrome that may include restlessness, hallucinations, loss of coordination, rapid heart rate, increased body temperature, rapid changes in blood pressure, hyperactive reflexes, diarrhea, coma, nausea, or vomiting.

In its most severe form, serotonin syndrome may resemble neuroleptic malignant syndrome (NMS). Among the signs and symptoms of NMS are a combination of fever, rapid heart rate, sweating, severe muscle rigidity, confusion, and increased muscle enzymes (determined by blood tests).

• Signs of infection such as high temperature, chills, tremors, headaches, sweating, and flu-like symptoms. This may be due to a hematological disorder that increases the risk of infection.
• Muscle pain, sensitivity, or weakness that is inexplicable. This may be a sign of rhabdomyolysis.

Frequency not known (cannot be estimated from available data)

• Signs and symptoms of a condition called“myocarditis due to stress”, which may include chest pain, difficulty breathing, dizziness, fainting, irregular heartbeats.

Other side effects that you should inform your doctor include (the frequency of these side effects is included in the list "Other side effects that may occur" below)

• Cough, wheezing, and difficulty breathing that may be accompanied by a high temperature.
• Stool that is tar-like or contains blood.
• Itching, yellowish skin or eyes, or dark urine that may be due to symptoms of liver inflammation (hepatitis).
• Cardiac problems, such as an irregular heart rate or increased blood pressure.
• Eye problems, such as blurred vision or dilated pupils.
• Nervous system problems, such as dizziness, numbness, movement disorders (muscle spasms or muscle rigidity), convulsions, or seizures.
• Psychiatric problems, such as hyperactivity and unusual feelings of overexcitement.
• Withdrawal effects (see the section"Venlafaxine Retard Viatris" and "If you stop takingVenlafaxine Retard Viatris").
• Prolonged bleeding: if you cut or injure yourself, bleeding may take a little longer to stop.

Do not worry if you see small white pellets or granules in your stool after taking this medicine. Inside the venlafaxine capsules are small white spheres that contain the active ingredient (venlafaxine). The spheres come out of the capsules in the stomach, and the venlafaxine is slowly released as the spheres move through the stomach to the intestine. The "shell" of the spheres does not dissolve and is deposited in the stool. This means that, despite seeing the spheres in the stool, the dose of the medicine has been absorbed.

Other possible side effects:

Very common (may affect more than 1 in 10 people)

• Dizziness; headache.
• Nausea; dry mouth.
• Drowsiness.
• Excessive sweating (including night sweats).
• Difficulty sleeping (insomnia).
• Constipation.

Common (may affect up to 1 in 10 people)

• Loss of appetite.
• Confusion, feeling disconnected (or detached) from oneself, lack of orgasm, decreased libido, agitation, nervousness, abnormal dreams.
• Visual disturbances, including blurred vision; dilated pupils; inability to automatically change focus from distant to near objects.
• Ringling in the ears (tinnitus).
• Increased blood pressure, flushing.
• Yawning.
• Discomfort (vomiting); diarrhea.
• Increased frequency of urination; inability to urinate, difficulty urinating.
• Irregular menstrual periods, such as increased bleeding or irregular bleeding; abnormal ejaculation/orgasm (men); erectile dysfunction (impotence).
• Weakness (asthenia); fatigue; chills.
• Increased cholesterol in the blood.
• Difficulty breathing.
• Moderate rash, itching.
• Weight gain; weight loss.

• Feeling of restlessness or inability to sit or stay still, numbness, altered sense of taste, increased muscle tone.

• Irregular heartbeats (palpitations).

Rare (may affect up to 1 in 1,000 people)

• Hyperactivity, accelerated thoughts, and decreased need for sleep (mania).

• Hallucinations, feeling disconnected (or detached) from reality, abnormal orgasms, lack of sensations or emotions, feeling overexcited, teeth grinding.
• Fainting, involuntary muscle movements, uncontrollable spasms, spasmodic or twisted movements, altered coordination and balance.
• Dizziness, especially when standing up quickly; decreased blood pressure.
• Vomiting with blood, tar-like stool, or blood in stool, which may be a sign of internal bleeding.
• Sensitivity to sunlight; bruises (ecchymosis); abnormal hair loss, urticaria.
• Low blood pressure.
• Ligero changes in liver enzymes in the blood, which may be observed through blood tests.
• Inability to control urination.
• Muscle rigidity, spasms, and involuntary muscle movements.

Rare (may affect up to 1 in 1,000 people)

• Decreased sodium levels in the blood, which may be observed through blood tests.
• Disorientation and confusion, often accompanied by hallucinations (delirium).
• Cough, wheezing, and difficulty breathing that may be accompanied by a high temperature.
• Excessive water intake (known as inappropriate secretion of antidiuretic hormone).
• Severe eye pain and blurred or decreased vision.
• Irregular heartbeats, rapid, or abnormal heartbeats, which may cause fainting.
• Severe abdominal or back pain (which may indicate a serious problem in the intestine, liver, or pancreas).
• Itching, yellowish skin or eyes, or flu-like symptoms, which indicate liver inflammation (hepatitis).

Very rare (may affect up to 1 in 10,000 people)

• Abnormal milk production.
• Prolonged bleeding, which may be a sign of a decrease in platelet count in the blood, which increases the risk of bruising or bleeding.
• Unexpected bleeding, such as bleeding gums, blood in urine or vomit, or unexpected bruising or rupture of blood vessels (hemorrhage).

Frequency not known (cannot be estimated from available data)

• Suicidal thoughts and behaviors; suicidal thoughts and behaviors have been reported during treatment with venlafaxine or shortly after stopping treatment (see section2, "What you need to know before starting to take Venlafaxine Retard Viatris").

• Aggression.
• Dizziness.
• Abundant vaginal bleeding shortly after delivery (postpartum hemorrhage), see “Pregnancy and breastfeeding” in section 2 for more information.

In some cases, venlafaxine may cause unwanted effects that you may not know about, such as high blood pressure or abnormal heartbeats, or slight changes in blood levels of liver enzymes, sodium, and cholesterol. Venlafaxine rarely reduces platelet function in the blood, which increases the risk of bruising or bleeding. Therefore, your doctor may wish to perform occasional blood tests, especially if you have been taking venlafaxine for a prolonged period.

Other side effects in children and adolescents

Although this medicine is not usually recommended for children and adolescents, cases of hostility, self-harm, stomach pain, indigestion, acid reflux, and muscle pain have also been reported.

Reporting side effects

If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date that appears on the box after CAD or EXP.The expiration date is the last day of the month indicated.

This medication does not require special storage conditions.

Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.

Composition of Venlafaxina Retard Viatris:

The active ingredient is venlafaxine.

Each prolonged-release hard capsule contains venlafaxine hydrochloride, equivalent to 75 mg and 150 mg of venlafaxine (as hydrochloride).

The other components are: hypromellose, ammonio methacrylate copolymer, sodium lauryl sulfate, magnesium stearate (E-572), basic butyl methacrylate copolymer.The capsule contains:titanium dioxide (E-171), gelatin, red iron oxide (E-172) (only for the 75 mg dose) and erythrosine (E-127) and indigo carmine (E-132) (only for the 150 mg dose). Printing ink: Shellac wax, black iron oxide (E-172).

Appearance of the product and contents of the package

Prolonged-release hard capsules of 75 mg:

Opaque, beige-colored, hard capsules, marked with the text “VEN” on the capsule cap and “75” on the capsule body.

Prolonged-release hard capsules of 150 mg:

Opaque, intense red-colored, hard capsules, marked with the text “VEN” on the capsule cap and “150” on the capsule body.

Available in blisters of 7, 10, 14, 20, 25, 28, 30, 50, 56, 70, 90, 100, 500, and 1000 capsules, single-dose perforated blisters of 30 capsules, multi-packs containing 90 capsules, included in 3 packs of 30 capsules each, multi-packs containing 100 capsules, included in 2 packs of 50 capsules each, and bottles containing 7, 10, 14, 20, 25, 28, 30, 50, 56, 70, 90, 100, and 250 capsules.

Only some package sizes may be commercially available.

Marketing authorization holder and responsible manufacturer

Marketing authorization holder:

Viatris Limited

Damastown Industrial Park

Mulhuddart, Dublin 15

Dublin

Ireland

Responsible manufacturer:

McDermott Laboratories Ltd. T/A - Gerard Laboratories

35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13

Ireland

or

Pharmathen International S.A.

Sapes Industrial Park, Block 5

69300 Rodopi

Greece

or

Pharmathen S.A.

6, Dervenakion str.

153 51 Pallini, Attiki

Greece

or

Pharma Pack Hungary Kft

Vasut utca 13. Kamaraerdo

2040 Budaörs

or

Mylan Hungary Kft

Mylan utca 1

H-2900 Komárom

Hungary

or

Europhartech

rue Henri Matisse

63370 Lempdes

France

or

Pharma Pack Hungary Kft

Vasut utca 13. Kamaraerdo

2040 Budaörs

or

Viatris Sante

ZAC des Gaulnes, 360 Avenue Henri Schneider

69330 Meyzieu

or

Viatris Sante

1 Rue de Turin

69007 Lyon

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

Viatris Pharmaceuticals, S.L.U.

C/ General Aranaz, 86

28027 - Madrid

Spain

This medication is authorized in the member states of the European Economic Area with the following names::

GermanyVenlafaxin dura 75 mg Hartkapseln, retardiert

AustriaVenlafaxin Arcana retard - Kapseln

BelgiumVenlafaxine Retard Mylan

SlovakiaVenlafaxin Mylan

Spain:Venlafaxina Retard Viatris hard prolonged-release capsules EFG

FranceVENLAFAXINE Viatris prolonged-release capsule

GreeceVenlafaxine/Mylan 75 mg/CAP Καψ?κιο παρατεταμ?νης αποδ?σμευσης, σκληρ?

IrelandVenlofex

ItalyVenlafaxina Mylan

NetherlandsVenlafaxine Retard Mylan

PolandFaxigen XL

PortugalVENLAFAXINA MYLAN

United KingdomVexarin XL prolonged release capsules, hard

Czech RepublicVenlafaxin Mylan

SwedenVenlafaxin Mylan

Last review date of this leaflet:July 2023

More detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)https://www.aemps.gob.es/